Skip to main content
Clinical Trials/NCT04995731
NCT04995731
Unknown
Not Applicable

Risk Assessment of Endometrial Hyperplasia and Endometrial Cancer: Development and Validation of Clinical-ultrasound Based Scoring System(A Cross Sectional -Validation Study)

Assiut University1 site in 1 country328 target enrollmentSeptember 1, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Endometrial Cancer
Sponsor
Assiut University
Enrollment
328
Locations
1
Primary Endpoint
prevalence of endometrial cancer, endometrial hyperplasia
Last Updated
3 years ago

Overview

Brief Summary

Abnormal uterine bleeding (AUB) represents common diagnostic challenge in everyday gynecological practice. However, abnormal bleeding is a common symptom of many benign diseases and only indicates the presence of EC in 9% of postmenopausal women and 1% to 2% of premenopausal women, suggesting that many women at low risk undergo unnecessary invasive procedures to rule out cancer. The aim of the study is to create a risk-scoring model of endometrial hyperplasia and endometrial cancer.

Detailed Description

Approximately 90% of endometrial cancer (EC) cases are preceded by AUB in premenopausal or perimenopausal women or post-menopausal bleeding (PMB).Transvaginal ultrasonography(TVS) has become the first step diagnostic tool of AUB. The main advantage of ultrasound imaging is that it has high accuracy for the preoperative classification of intra and extra uterine lesions, both benign and malignant. If increased endometrial thickness (ET) is found in women with PMB, the risk of EC increases. However, in women with type II EC, ET below 3-4 mm might also be found. Because of these limitations, ET should not be the only factor for cancer risk estimation in women with AUB. Three-dimensional sonography and blood flow vascular indices improve the diagnostic precision of the sonographic estimation of endometrial lesions. Several scoring systems using different ultrasound image characteristics were proposed to estimate the risk of EC in women with AUB including the recently proposed system" Risk of Endometrial Cancer scoring model "(REC). Existing guidelines recommend considering clinical risk factors such as BMI, age, obesity, type II diabetes, polycystic ovary syndrome(PCOS) and use of unopposed estrogen when evaluating AUB. However, only few clinical risk prediction models have been developed. Despite the important role of ultrasound imaging in assessment of endometrial lesions, one wonders if clinical variables can improve the diagnostic performance of risk prediction models. The aim of the study is to create a risk-scoring model of endometrial hyperplasia and endometrial cancer using patient clinical characteristics and ultrasound image characteristics among women with abnormal uterine bleeding, and to validate the diagnostic performance of our model and to compare it's predictive value with the recently proposed REC score for EC risk stratification.

Registry
clinicaltrials.gov
Start Date
September 1, 2021
End Date
July 2024
Last Updated
3 years ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Norhan Tarek Sayed

assistant lecturer of obstetrics and gynecology, Faculty of medicine

Assiut University

Eligibility Criteria

Inclusion Criteria

  • women ≥40 years with pre- or perimenopausal AUB or PMB presenting to Women's Health Hospital, Department of Obstetrics and Gynecology, Faculty of medicine, Assiut University, Assiut, Egypt.

Exclusion Criteria

  • Women with a vaginal bleeding arising from a cervical, vaginal or vulvar disease.
  • Patients with cervical cancer or uterine metastases.
  • History of prior hysterectomy, prior pelvic radiation, endometrial sampling within the past 3 months.
  • Presence of existing pregnancy.
  • Women with inadequate endometrial sampling or with no histopathological diagnosis.

Outcomes

Primary Outcomes

prevalence of endometrial cancer, endometrial hyperplasia

Time Frame: 3 years

Magnitude and prevalence of endometrial cancer, endometrial hyperplasia using a practical clinical-ultrasound based scoring system.

Secondary Outcomes

  • prevalence of endometrial benign lesions(3 years)

Study Sites (1)

Loading locations...

Similar Trials